Hepatocellular carcinoma future treatment options
Authors:
MUDr. Tomášek Jiří, Ph.D.; doc. MUDr. Kiss Igor; Ph.D. Mba
Authors‘ workplace:
Klinika komplexní onkologické péče LF MU a MOÚ, Brno
Published in:
Klin Onkol 2020; 33(Supplementum 3): 26-29
Category:
Review
doi:
https://doi.org/10.14735/amko20203S26
Overview
Background: The algorithm for diagnosing and treating HCC has been relatively stable for many years. In the last few years, there has been clear progress, which is reflected in the international recommendations and in our recommendations, which are set out in the Blue Book of the Czech Oncological Society.
Purpose: Current developments in the diagnosis and treatment of hepatocellular carcinoma (HCC) are well illustrated by selected presentations from this year‘s Gastrointestinal Cancers Symposium in San Francisco and the American Society for Clinical Oncology Annual Meeting 2020. The review will focus on selected news from the diagnostics as well as surgical and interventional treatment of HCC, systemic treatment and a combination of these modalities.
Keywords:
hepatocellular carcinoma – interventional radiology – surgery – immunotherapy – molecular targeted therapy
Sources
1. Chalasani NP, Bhattacharya A, Book A et al. Algorithm for blood-based panel of methylated DNA and protein markers to detect early stage hepatocellular carcinoma with high specificity. ASCO 2020; abstract 4577.
2. Huang G. Associating liver partition and portal vein ligation for staged hepatectomy versus portal vein embolization in staged hepatectomy for hepatocellular carcinoma: A randomized comparative study. ASCO 2020; abstract 4578.
3. Nugent FW, Hunter K, Molgaard CH et al. A randomized phase II feasibility study of individualized stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) with DEBDOX beads as a bridge to transplant in hepatocellular carcinoma (HCC). ASCO 2020; abstract 4586
4. Gadodia G, Yanof J, West K et al. True 3D holographic visualization for performance of percutaneous thermal ablation of solid liver tumors (3D-HPA): An update on in-human evaluation. ASCO 2020; abstract 297.
5. Ntourakis D, Memeo R, Soler L et al. Augmented reality guidance for the resection of missing colorectal liver metastases: An initial experience. World J Surg 2016; 40 (2): 419–426. doi: 10.1007/s00268-015-3229-8.
6. Tateishi R, Hasegawa K, Kawaguchi Y et al. A multicenter nonrandomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF cohort trial). ASCO 2020; abstract 4581.
7. Ikeda M, Inaba Y, Tanaka T et al. A prospective randomized controlled trial of selective transarterial chemoembolization using drug-eluting beads loaded with epirubicin versus selective conventional transarterial chemoembolization using epirubicin-lipiodol for hepatocellular carcinoma: The JIVROSG-1302 PRESIDENT study. ASCO 2020; abstract 4518.
8. Chen S. Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with unresectable hepatocellular carcinoma (HAIROX): A phase II, single-arm, prospective study. ASCO 2020; abstract 4574.
9. Wei W, Wang Q, Guo Z et al. Postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: A preliminary report of a phase III, randomized, controlled clinical trial. ASCO GI 2020; abstract 527.
10. Zhou L, Xu Y, Wang D et al. Perioperative circulating tumor DNA analysis to predict patient prognosis in liver cancer. ASCO 2020; abstract 4593.
11. Fínek J. Hepatocelulární karcinom – dlouhodobě léčitelné onemocnění. Klin Onkol 2012; 25 (4): 287– 289.
12. Alsina A, Kudo M, Vogel A et al. Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC). ASCO GI 2020; abstract 520.
13. Feng B, Shukui Q, Shanzhi G et al. Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial. ASCO 2020; abstract 4506.
14. Kudo M, Finn RS, Edeline J et al. Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC). ASCO GI 2020; abstract 518.
15. Kudo M, Lim HY, Cheng A et al. Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup. ASCO GI 2020; abstract 526.
16. Edeline J, Karwal M, Zhu AX et al. RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro). ASCO GI 2020; abstract 528.
17. Pinato DJ, Kaseb AO, Wang Y et al. Impact of baseline and concomitant corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. ASCO GI 2020; abstract 531.
18. Chan SL, Zhu AX, Finn RS et al. Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE224 and KEYNOTE-240. ASCO 2020; abstract 4587.
19. Kelley RK, Sangro B, Harris WP et al. Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). ASCO 2020; abstract 4508.
20. El Khoueiry AB, Kim RD, Garris WP et al. Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). ASCO GI 2020; abstract 564.
21. Zhu AX, Finn RS, Ikeda M et al. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). ASCO 2020; abstract 4519.
22. Jiao SC, Bai L, Dong J et al. Clinical activity and safety of penpulimab (Anti-PD-1) with anlotinib as first-line therapy for advanced hepatocellular carcinoma (HCC). ASCO 2020; abstract 4592.
23. Harding JJ, Yarmohammadi H, Reiss KA et al. Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Preliminary results from a phase I study of patients (pts) with liver limited hepatocellular carcinoma (HCC). ASCO GI 2020; abstract 525.
24. Tai WMD, Loke KSH, Gogna A. et al. A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678. ASCO 2020; abstract 4590.
Labels
Paediatric clinical oncology Surgery Clinical oncology Gastroenterology and hepatologyArticle was published in
Clinical Oncology
2020 Issue Supplementum 3
Most read in this issue
- Hepatocellular carcinoma future treatment options
- Current treatment options for hepatocellular carcinoma
- Hepatocellular carcinoma – imaging methods and imaging guided therapy
- Hepatocellular carcinoma from the view of gastroenterologist/hepatologist